Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.1100 USD
−21.49 M USD
8.95 M USD
187.59 M
About Lineage Cell Therapeutics, Inc.
Sector
Industry
CEO
Brian M. Culley
Website
Headquarters
Carlsbad
Founded
1990
FIGI
BBG000G8RJY6
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of LCTX is 0.5989 USD — it has increased by 2.92% in the past 24 hours. Watch Lineage Cell Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Lineage Cell Therapeutics, Inc. stocks are traded under the ticker LCTX.
LCTX stock has risen by 12.41% compared to the previous week, the month change is a −29.93% fall, over the last year Lineage Cell Therapeutics, Inc. has showed a −39.10% decrease.
We've gathered analysts' opinions on Lineage Cell Therapeutics, Inc. future price: according to them, LCTX price has a max estimate of 5.00 USD and a min estimate of 2.00 USD. Watch LCTX chart and read a more detailed Lineage Cell Therapeutics, Inc. stock forecast: see what analysts think of Lineage Cell Therapeutics, Inc. and suggest that you do with its stocks.
LCTX reached its all-time high on Oct 31, 1997 with the price of 24.9421 USD, and its all-time low was 0.0924 USD and was reached on Nov 7, 2005. View more price dynamics on LCTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
LCTX stock is 3.45% volatile and has beta coefficient of 0.63. Track Lineage Cell Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Lineage Cell Therapeutics, Inc. there?
Today Lineage Cell Therapeutics, Inc. has the market capitalization of 111.15 M, it has decreased by −30.59% over the last week.
Yes, you can track Lineage Cell Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Lineage Cell Therapeutics, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
LCTX earnings for the last quarter are −0.02 USD per share, whereas the estimation was −0.04 USD resulting in a 50.00% surprise. The estimated earnings for the next quarter are −0.03 USD per share. See more details about Lineage Cell Therapeutics, Inc. earnings.
Lineage Cell Therapeutics, Inc. revenue for the last quarter amounts to 3.78 M USD, despite the estimated figure of 1.03 M USD. In the next quarter, revenue is expected to reach 1.67 M USD.
LCTX net income for the last quarter is −3.03 M USD, while the quarter before that showed −5.76 M USD of net income which accounts for 47.33% change. Track more Lineage Cell Therapeutics, Inc. financial stats to get the full picture.
No, LCTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 3, 2024, the company has 75.00 employees. See our rating of the largest employees — is Lineage Cell Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Lineage Cell Therapeutics, Inc. EBITDA is −22.10 M USD, and current EBITDA margin is −268.76%. See more stats in Lineage Cell Therapeutics, Inc. financial statements.
Like other stocks, LCTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lineage Cell Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lineage Cell Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lineage Cell Therapeutics, Inc. stock shows the strong sell signal. See more of Lineage Cell Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.